Biosimilar is a term we in the autoimmune community need to be familiar with. Let’s answer the why first. The desire of affordability to treat RA (rheumatoid arthritis). Biologics currently on the market are costly and some of their patents are about to expire. This creates an opportunity for highly similar biological products to be manufactured. Now, just what is a biosimilar? Biologics, such as brand name Humira or Enbrel used to decrease inflammation in RA patients, are derived from living cell organisms using biological manufacturing processes. They have large complex protein structures. A biosimilar is highly similar to an already FDA-approved biological product available at this time. It is not exactly the same, like a generic drug product, but it is highly similar. Hence the name biosimilar.